Clinical Trial

Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People

Study acronym: NMNAGING
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2026 (before its estimated May 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-09; most recent amendment 2026-05-04.
Status change: Active, Not Recruiting → Recruiting 2025-06-25
Trial Details
NCT Number NCT06592859
Lead Sponsor People's Hospital of Quzhou
Collaborators: Beijing Institute of Genomics, Chinese Academy of Sciences, Institute of Zoology, Chinese Academy of Sciences
Conditions Aging, NMN
Enrollment 240 participants
Start Date 2023-08-23
Primary Completion 2026-05-24 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08